Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Sankyo’s Edoxaban Steps Up As Once-Daily Competitor To Xarelto

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo plans to file two once-daily doses of the edoxaban for stroke prevention in atrial fibrillation, but the lowest one was associated with more ischemic strokes compared to warfarin in the ENGAGE AF-TIMI 48 study, which could limit prospects for use.

You may also be interested in...

Eliquis Label Looks Great, But May Leave Door Open For Pradaxa To Compete On Efficacy

Bristol/Pfizer’s Eliquis secures an attractive FDA label for atrial fibrillation on three key fronts: superior stroke prevention, reduced major bleeding and reduced all-cause mortality. With its superiority in preventing hemorrhagic strokes, Eliquis has the clear lead in terms of safety. But Boehringer’s competing Pradaxa remains the only new oral anticoagulant with proven superiority for preventing purely ischemic strokes, which is the main goal of atrial fibrillation treatment.

Xarelto Takes Lead In Exploiting VTE Market Opportunity

J&J/Bayer’s Xarelto currently has the broadest label among new anticoagulants, with a new indication in the U.S. for venous thromboembolism. But Bristol/Pfizer’s Eliquis is also being positioned for broader use in VTE, with positive data reported at the American Society of Hematology meeting in December.

FDA Pradaxa Approval Balances Efficacy And Bleeding Risk

Boehringer Ingelheim GmbH's breakthrough anticoagulant Pradaxa (dabigatran) will be available to physicians and patients in the "next several days," the company said after FDA cleared the drug Oct. 19.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts